1 / 65

InFUSE ™ Bone Graft / LT-CAGE ™ Lumbar Tapered Fusion Device IDE Clinical Results G960065

InFUSE ™ Bone Graft / LT-CAGE ™ Lumbar Tapered Fusion Device IDE Clinical Results G960065. Hallett H. Mathews, M.D. Richmond, Virginia. Important Findings. Primary study objective met High fusion rates Shorter operative times and less blood loss

isi
Télécharger la présentation

InFUSE ™ Bone Graft / LT-CAGE ™ Lumbar Tapered Fusion Device IDE Clinical Results G960065

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. InFUSE™ Bone Graft /LT-CAGE ™ Lumbar Tapered Fusion DeviceIDE Clinical ResultsG960065 Hallett H. Mathews, M.D.Richmond, Virginia

  2. Important Findings • Primary study objective met • High fusion rates • Shorter operative times and less blood loss • Avoided complications and pain associated with bone graft harvesting

  3. InFUSE™Bone Graft versus Autograft Harvested from Iliac Crest

  4. Clinical Trial Results

  5. Clinical Trial DesignOpen Surgical Approach • Prospective, randomized controlled design • Investigational Treatment - LT-CAGE™ Device / InFUSE™ Bone Graft • Control Treatment - LT-CAGE ™ Device / autogenous bone

  6. Study Objectives • Primary Objective Equivalence in Overall Success • Secondary Objectives

  7. Study Entrance Criteria • Single level • Symptomatic degenerative disc disease • Inclusion/exclusion criteria

  8. Patient Evaluation • Preoperatively • Surgery/Discharge • Postoperatively: 6 Weeks, 3 Months, 6 Months 12 Months, 24 Months

  9. Patient Population • Patients - 143 received InFUSE™ Bone Graft - 136 received autogenous bone graft • 16 Investigational Centers

  10. Demographic Information

  11. Surgery Data

  12. Study Results Based on 24-Month Data

  13. Overall Success • Fusion •  15 point improvement in Oswestry score • Neurological maintenance or improvement • No serious adverse event possibly associated to the device • No second surgery failure

  14. Overall Success Rates

  15. Achieved Primary Objective

  16. Safety Overview • Adverse events • Second surgery procedures • Antibody formation

  17. Adverse Events

  18. Adverse Events

  19. Comparison of Adverse Eventsin Investigational and ControlTreatment Groups

  20. Differences noted in: • Graft Site Events - Occurred in 6% of control group None in investigational group • Urogenital Resolved prior to discharge

  21. Adverse Events • Typical for patient population • Not unanticipated

  22. Second Surgery Procedures

  23. Classifications • Revisions • Removals • Supplemental Fixations • Reoperations • Other

  24. Classifications • Revisions - Failure • Removals - Failure • Supplemental Fixations - Failure • Reoperations • Other

  25. Second Surgeries

  26. Assessment of Antibody Formation • rhBMP-2 • Bovine Type I Collagen • Human Type I Collagen

  27. Comparision ofAuthentic Positive ResponsesSimilar for both groups • One patient in each group had positive response to rhBMP-2. (<1%) • 13% in each group had positive response to bovine Type I collagen. None of these patients had positive results for human Type I collagen.

  28. Safety Summary Investigational and Control group rates are similar for: • Adverse events and second surgery procedures • Antibody responses InFUSE™ Bone Graft eliminates graft harvesting adverse events and pain

  29. InFUSE™ Bone Graft / LT-CAGE™ Device Safe for its intended use

  30. Effectiveness OverviewInFUSE™ Bone Graft / LT-CAGE™ Device patients had: • High fusion rates • Pain relief • Maintenance or improvement in neurological status

  31. Fusion • Primary endpoint • CT scans and radiographs utilized • Two teams of independent reviewers

  32. Fusion Criteria • Radiographic - Bridging trabecular bone - Segmental stability - Lucent line criteria • No “pseudarthrosis” second surgery

  33. Fusion Success Rates

  34. Oswestry Low Back PainDisability Questionnaire

  35. Mean Oswestry Scores

  36. Oswestry Success 15 Point Improvement

  37. Neurological Status Measurements • Motor Function • Sensory • Reflexes • Straight Leg Raise

  38. Neurological Success Rates

  39. Secondary Effectiveness Endpoints • Back pain • Leg pain • Disc height maintenance • SF-36

  40. Back Pain Results - 24 Months

  41. Graft Site Pain in Control PatientsMean Scores

  42. Graft Site Appearance in Control Patients

  43. Use of InFUSE™Bone Graft eliminates: Negatives of Graft-site Appearance, Pain and Morbidity

  44. Laparoscopic Clinical Trial • Data augment safety profile • Supports approval of implantation method • Identical protocol to open study • 134 Investigational patients • 14 Sites

  45. Surgery Data - Laparoscopic • 2 days shorter hospital stay • 45% treated on outpatient basis • Returned to work 20 days sooner

  46. Overall Success Rates - Laparoscopic Study

  47. Safety Results - Comparable to Open Surgical Treatment Group

  48. Laparoscopic Versus Control 24 Months

  49. Fusion Success Rates - Laparoscopic Study

  50. Case Histories

More Related